NEW YORK, Dec. 30 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that the Company will host its quarterly update conference call at 4:30 PM Eastern Time on Thursday, January 22, 2009. Richard Taney, President and Chief Executive Officer of Delcath Systems, will host the call. Mr. Taney will discuss the progress of patient enrollment and the advancement of clinical studies. A question and answer session will immediately follow management's prepared remarks.
Joining Mr. Taney on the call will be Mark Morrison, MD, PhD, Chief Medical Officer; Jonathan Foltz, Executive Vice President; John Talarico, Senior Vice President Regulatory Affairs and Quality Systems; and Jason Rifkin, Senior Vice President Clinical Operations. Mr. Taney will also introduce Barbra Keck, Delcath's recently hired Controller. Ms. Keck will assume the responsibilities of Principal Accounting Officer following the previously announced departure of Delcath's Chief Financial Officer.
Mr. Taney commented, "2008 was a transformational year for Delcath. We expanded our pivotal Phase III FDA trial from our base at the National Cancer Institute to 10 regionally diversified leading cancer hospitals and passed the important milestone of 50% of patient enrollment. We have also conserved cash resources and assembled a first class executive team and Board of Directors to execute on our clinical and financial milestones as we prepare for commercialization. I look forward to speaking with the investment community in a few weeks to share our excitement for 2009."
The call will be available live and archived via the Delcath website. In addition, the call can be accessed via telephone; dial-in information will be provided a few days prior to the call.
About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
|SOURCE Delcath Systems, Inc.|
Copyright©2008 PR Newswire.
All rights reserved